Physician profile
Steven P Johnson
NPI 1306831284
$3,265.37
in general payments reported to CMS, 2019-2025
41 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $582 · 2021: $314 · 2022: $409 · 2023: $424 · 2024: $468 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $393.96 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $362.63 | 2019-2024 | |
| Antares Pharma, INC. | $357.24 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Glaxosmithkline, LLC. | $280.40 | 2019-2022 | |
| Novo Nordisk INC | $210.32 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $195.75 | 2019-2024 | Spravato |
| Abbvie INC. | $179.18 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $114.41 | 2019-2023 | Farxiga |
| Amgen INC. | $95.02 | 2019-2023 | Otezla, Repatha |
| Halozyme INC | $80.71 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.68 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $75.70 | 2019-2021 | |
| Allergan, INC. | $73.25 | 2019-2020 | |
| Neos Therapeutics, LP | $67.10 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $64.45 | 2020-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.